Valuation: BICO Group AB

Market Cap 967M 99.8M 87.48M 80.86M 74.37M 140M 9.62B 143M 379M 4.71B 375M 367M 16.22B P/E 2026 *
-4.68x
P/E 2027 * -8.64x
Enterprise Value 909M 93.78M 82.2M 75.98M 69.88M 132M 9.04B 134M 356M 4.42B 352M 344M 15.24B EV / Sales 2026 *
0.58x
EV / Sales 2027 * 0.53x
Free-Float
68.5%
Yield 2026 *
-
Yield 2027 * -
1 day+1.84%
1 week-1.90%
Current month-12.03%
1 month-12.03%
3 months-33.03%
6 months-31.42%
Current year-36.99%
1 week 1.52
Extreme 1.522
1.55
1 month 1.52
Extreme 1.522
1.58
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
3.95
3 years 1.52
Extreme 1.522
6.9
5 years 0
Extreme 0
100
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 54 26/11/2023
Director of Finance/CFO 56 28/02/2026
Chief Operating Officer - 06/01/2026
Director TitleAgeSince
Director/Board Member 70 17/12/2019
Director/Board Member 65 07/05/2025
Chairman 51 15/09/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-1.90% - - 102M
-1.17%-0.16%+26.88%-1.74% 198B
-1.33%+1.03%+5.82%-17.54% 144B
+2.24%-13.25%-31.57%+1.58% 122B
-0.59%-2.23%-57.77%-16.37% 65.44B
-0.85%-7.82%+11.13%-7.23% 49.36B
+0.65%+2.20%-23.34%-30.88% 44.74B
-0.91%-3.00%+14.27%+5.83% 37.13B
-3.10%-5.02%+24.35%+27.66% 36.23B
-0.19%-2.58%-23.00%-8.92% 28.7B
Average -0.32%-2.81%-5.91%-5.29% 80.68B
Weighted average by Cap. -0.44%-2.62%-1.69%-6.24%

Financials

2026 *2027 *
Net sales 1.57B 162M 142M 131M 120M 227M 15.59B 231M 614M 7.63B 607M 594M 26.28B 1.69B 174M 153M 141M 130M 245M 16.81B 249M 662M 8.22B 654M 640M 28.33B
Net income -207M -21.33M -18.7M -17.28M -15.89M -29.99M -2.06B -30.47M -81.01M -1.01B -80.1M -78.35M -3.47B -112M -11.56M -10.13M -9.37M -8.61M -16.25M -1.11B -16.51M -43.9M -545M -43.41M -42.46M -1.88B
Net Debt -58.35M -6.02M -5.28M -4.88M -4.49M -8.47M -581M -8.6M -22.87M -284M -22.62M -22.12M -979M -64.95M -6.7M -5.88M -5.43M -5M -9.43M -647M -9.58M -25.46M -316M -25.17M -24.63M -1.09B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
557
Date Price Change Volume
17/07/26 US$1.550 +1.84% 500
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
13.92SEK
Average target price
31.00SEK
Spread / Average Target
+122.70%

Quarterly revenue - Rate of surprise